HT Guard Spółka z Ograniczoną Odpowiedzialnością (KRS 0000719417, NIP 6312677135) is a Polish company, headquartered in Sosnowiec, Śląskie voivodeship. HT GUARD operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since February 21, 2018. HT GUARD's most recently reported net revenue was 0 PLN for 2024.
Historical suspension of activities
Suspension: July 1, 2022 - resumed: July 2, 2024
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - HT Guard
Identity
- Name
- HT Guard Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 21, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- July 15, 2025
- Founding act
- 08.12.2017 R., NOTARIUSZ JACEK TURSKI, KANCELARIA NOTARIALNA W GLIWICACH, REP. A NR 6409/2017, 01.02.2018 R., NOTARIUSZ …
Articles of association history (3)
- December 8, 2017: 08.12.2017 R., NOTARIUSZ JACEK TURSKI, KANCELARIA NOTARIALNA W GLIWICACH, REP. A NR 6409/2017, 01.02.2018 R., NOTARIUSZ JACEK TURSKI, KANCELARIA NOTARIALNA W GLIWICACH, REP. A NR 498/2018 - ZMIENIONO: §3, §11 PKT 2, §12, §21 UST.2, §21 UST.4, §25 UST.6, §29 UST.2,
- October 4, 2019: 04.10.2019R., REP. A NR 4471/2019, NOTARIUSZ MARIUSZ CEBULSKI, KANCELARIA NOTARIALNA AL. KORFANTEGO 25 44-100 GLIWICE ZMIENIONO: PAR.9, PAR.11 UMOWY
- January 4, 2025: 1.04.2025 R., REP. A NR 5184/2025, NOTARIUSZ PAWEŁ KURIATA, KANCELARIA NOTARIALNA W JELCZU - LASKOWICACHPRZY UL. BOŻKA NR 11B -UCHYLENIE DOTYCHCZASOWEJ TREŚCI UMOWY SPÓŁKI I PRZYJĘCIE NOWEGO TEKSTU UMOWY SPÓŁKI.
Activities
Main activity
72.10.ZScientific research and development
Other activities
Address and contact
- Address
- UL. WOJSKA POLSKIEGO, 8, 41-208, SOSNOWIEC, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- SOSNOWIEC
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-88642-74475-HWAHT-26
- Coordinates
- 50.3167, 19.2394approx.
Risk and payment profile - HT Guard
Credibility rating
28.1 / 100
Poor credibility
Insolvency risk
Moderate
Elevated threat
Closure risk
55
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/8 yrs
Board changes
1
1/8 yrs
PKD changes
1
1/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (28/100)
Trend: stable (+0.3 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - HT Guard
Founded
February 21, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
SOSNOWIEC
ŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
50.0 K PLN
1,000 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
7 years
2018–2024 · profitable: 0/7
Registry entries
25
latest: July 15, 2025
Risk signals
Revenue
0 PLN
2024
Net profit
-64.8 K PLN
2024
Assets
723.1 K PLN
2024
Equity
39.9 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
390.8 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - HT Guard.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
